alpha 2A-adrenergic receptor Agonists
1 drugsAbout alpha 2A-adrenergic receptor
The alpha 2A-adrenergic receptor is a G protein-coupled receptor in the alpha-adrenergic family, primarily located within the central nervous system. It regulates neurotransmitter release, especially norepinephrine, influencing attention, cognition, and blood pressure.
The α2A-adrenergic receptor is a therapeutic target for neurological and psychiatric conditions; however, there is currently no genetic evidence directly linking this receptor to specific diseases.
INTUNIV (Takeda) is the only FDA-approved drug targeting this receptor, a small molecule approved in 2009 for CNS indications. Further research may lead to novel treatments where current therapies are insufficient.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Depression with only 1 trials.
Top alpha 2A-adrenergic receptor Drugs
Takeda is the only company with an approved drug (INTUNIV) targeting the alpha 2A-adrenergic receptor.
The market is not highly competitive, presenting an opportunity for new entrants to develop novel therapies.
alpha 2A-adrenergic receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets alpha 2A-adrenergic receptor, using small molecule modality.
Explore alternative modalities like antibodies or biologics to differentiate from existing treatments.
alpha 2A-adrenergic receptor Clinical Trials 29 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 | 100% |
| Phase 2 | 12 | 10 | 1 | 1 | 91% |
| Phase 3 | 8 | 7 | 0 | 1 | 100% |
| Phase 4 | 7 | 7 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
alpha 2A-adrenergic receptor Drug Approval Timeline (2009 - 2009)
The first and only drug, INTUNIV, was approved in 2009, indicating a long period without new approvals.
The lack of recent approvals suggests potential for innovation and unmet needs in this therapeutic area.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 17 clinical trials targeting alpha 2A-adrenergic receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities